Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 244

1.

IS TENOFOVIR SUPERIOR THAN ENTECAVIR IN REDUCING THE RISK OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B? THE CONTROVERSY CONTINUES.

Lampertico P, Papatheodoridis GV.

Gastroenterology. 2019 Nov 7. pii: S0016-5085(19)41524-2. doi: 10.1053/j.gastro.2019.11.007. [Epub ahead of print] No abstract available.

PMID:
31706943
2.

Nucleos(t)ide Analog Therapy of Chronic Hepatitis B and Liver Cancer Risk Reduction: Better Nucleotides than Nucleosides?

Lampertico P, Colombo M.

Gastroenterology. 2019 Oct 14. pii: S0016-5085(19)41448-0. doi: 10.1053/j.gastro.2019.10.011. [Epub ahead of print] No abstract available.

PMID:
31622619
3.

Focus on Very Late Hepatocellular Carcinoma Recurring After Liver Transplantation: A Case Report and Literature Review.

Invernizzi F, Maggi U, Mazza S, Baia M, Nosotti M, Mendogni P, Muiesan P, Cannata A, Iavarone M, Damarco F, Lampertico P, Donato MF, Rossi G.

Transplant Proc. 2019 Nov;51(9):2998-3000. doi: 10.1016/j.transproceed.2019.04.095. Epub 2019 Oct 10.

PMID:
31607618
4.

EXPERIENCE WITH EARLY SORAFENIB TREATMENT WITH mTOR INHIBITORS IN HEPATOCELLULAR CARCINOMA RECURRING AFTER LIVER TRANSPLANTATION.

Invernizzi F, Iavarone M, Zavaglia C, Mazza S, Maggi U, Cesarini L, Antonelli B, Airoldi A, Manini MA, Sangiovanni A, Rossi G, Donato MF, Belli LS, Lampertico P.

Transplantation. 2019 Sep 9. doi: 10.1097/TP.0000000000002955. [Epub ahead of print]

PMID:
31517781
5.

Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.

Degasperi E, Spinetti A, Lombardi A, Landonio S, Rossi MC, Pasulo L, Pozzoni P, Giorgini A, Fabris P, Romano A, Lomonaco L, Puoti M, Vinci M, Gatti F, Carolo G, Zoncada A, Bonfanti P, Russo FP, Aghemo A, Soria A, Centenaro R, Maggiolo F, Rovere P, Pasin F, Paon V, Faggiano G, Vario A, Grossi G, Soffredini R, Carriero C, Paolucci S, Noventa F, Alberti A, Lampertico P, Fagiuoli S; NAVIGATORE-Lombardia and Veneto Study Groups.

J Hepatol. 2019 Aug 6. pii: S0168-8278(19)30461-1. doi: 10.1016/j.jhep.2019.07.020. [Epub ahead of print]

PMID:
31433303
6.

Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis.

Sigon G, D'Ambrosio R, Clerici M, Pisano G, Chantarangkul V, Sollazzi R, Lombardi R, Peyvandi F, Lampertico P, Fargion S, Tripodi A, Fracanzani AL.

Liver Int. 2019 Aug 16. doi: 10.1111/liv.14213. [Epub ahead of print]

PMID:
31419372
7.

Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation.

Iavarone M, Invernizzi F, Czauderna C, Sanduzzi-Zamparelli M, Bhoori S, Amaddeo G, Manini MA, López MF, Anders M, Pinter M, Rodríguez MJB, Cristóbal MR, Soteras GA, Piñero F, Villadsen GE, Weinmann A, Crespo G, Mazzaferro V, Regnault H, Giorgio M, González-Diéguez ML, Donato MF, Varela M, Wörns MA, Bruix J, Lampertico P, Reig M.

Am J Transplant. 2019 Jul 31. doi: 10.1111/ajt.15551. [Epub ahead of print]

PMID:
31365177
8.

Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B.

Le Bert N, Salimzadeh L, Gill US, Dutertre CA, Facchetti F, Tan A, Hung M, Novikov N, Lampertico P, Fletcher SP, Kennedy PTF, Bertoletti A.

J Hepatol. 2019 Jul 23. pii: S0168-8278(19)30424-6. doi: 10.1016/j.jhep.2019.07.015. [Epub ahead of print]

PMID:
31348999
9.

Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy.

Loglio A, Iavarone M, Viganò M, Orenti A, Facchetti F, Cortinovis I, Lunghi G, Ceriotti F, Occhipinti V, Rumi M, Sangiovanni A, Colombo M, Lampertico P.

Liver Int. 2019 Oct;39(10):1964-1974. doi: 10.1111/liv.14197. Epub 2019 Aug 12.

PMID:
31323159
10.

Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients.

Loglio A, Ferenci P, Uceda Renteria SC, Tham CYL, van Bömmel F, Borghi M, Holzmann H, Perbellini R, Trombetta E, Giovanelli S, Greco L, Porretti L, Prati D, Ceriotti F, Lunghi G, Bertoletti A, Lampertico P.

J Hepatol. 2019 Oct;71(4):834-839. doi: 10.1016/j.jhep.2019.07.003. Epub 2019 Jul 11.

PMID:
31302176
11.

Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB - Is one NUC better than the other?

Wong GL, Lampertico P.

J Hepatol. 2019 Sep;71(3):453-455. doi: 10.1016/j.jhep.2019.05.017. Epub 2019 Jun 14. No abstract available.

PMID:
31208894
12.

TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals.

Degasperi E, Galmozzi E, Facchetti F, Farina E, D'Ambrosio R, Soffredini R, Iavarone M, Lampertico P.

J Viral Hepat. 2019 Oct;26(10):1233-1236. doi: 10.1111/jvh.13155. Epub 2019 Jun 30.

PMID:
31177595
13.

Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance.

Iavarone M, Viganò M, Piazza N, Occhipinti V, Sangiovanni A, Maggioni M, D'Ambrosio G, Forzenigo LV, Motta F, Lampertico P, Rumi MG, Colombo M.

Ann Hepatol. 2019 Mar - Apr;18(2):318-324. doi: 10.1016/j.aohep.2018.09.002. Epub 2019 Apr 17.

14.

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.

Yurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O, Gane EJ, Gish RG, Glenn JS, Hamid S, Heller T, Koh C, Lampertico P, Lurie Y, Manns M, Parana R, Rizzetto M, Urban S, Wedemeyer H; Hepatitis Delta International Network (HDIN).

J Hepatol. 2019 May;70(5):1008-1015. doi: 10.1016/j.jhep.2018.12.022. Epub 2018 Dec 27. Review.

PMID:
30982526
15.

A global scientific strategy to cure hepatitis B.

Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim SG, Lu F, Penicaud MC, Tavis JE, Thimme R; Members of the ICE-HBV Working Groups; ICE-HBV Stakeholders Group Chairs; ICE-HBV Senior Advisors, Zoulim F.

Lancet Gastroenterol Hepatol. 2019 Jul;4(7):545-558. doi: 10.1016/S2468-1253(19)30119-0. Epub 2019 Apr 10. Erratum in: Lancet Gastroenterol Hepatol. 2019 Jul;4(7):e7.

16.

Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B.

Wei L, Pavlovic V, Bansal AT, Chen X, Foster GR, He H, Kao JH, Lampertico P, Liaw YF, Motoc A, Papatheodoridis GV, Piratvisuth T, Plesniak R, Wat C.

J Viral Hepat. 2019 Sep;26(9):1040-1049. doi: 10.1111/jvh.13107. Epub 2019 Jul 23.

PMID:
30972912
17.

Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipients.

D'Ambrosio R, Vinci M, Franchina M, Parlati L, Zaltron S, Pasulo L, Campise M, Messa P, Pol S, Lampertico P.

Kidney Int. 2019 Apr;95(4):993-995. doi: 10.1016/j.kint.2018.11.037. No abstract available.

PMID:
30904073
18.

Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data.

Pavlovic V, Yang L, Chan HL, Hou J, Janssen HL, Kao JH, Lampertico P, Peng CY, Piratvisuth T, Thompson AJ, Wedemeyer H, Wei L, Wat C.

Antivir Ther. 2019;24(2):133-140. doi: 10.3851/IMP3304.

PMID:
30865588
19.

Hepatitis C virus-induced glomerular disease and posterior reversible encephalopathy syndrome after liver transplant: Case report and literature review.

Fabrizi F, Paolucci A, Antonelli B, Cerutti R, Donato FM, Lampertico P, Messa P.

Saudi J Kidney Dis Transpl. 2019 Jan-Feb;30(1):239-249.

20.

A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms.

Sharkawy RE, Bayoumi A, Metwally M, Mangia A, Berg T, Romero-Gomez M, Abate ML, Irving WL, Sheridan D, Dore GJ, Spengler U, Lampertico P, Bugianesi E, Weltman M, Mollison L, Cheng W, Riordan S, Santoro R, Gallego-Durán R, Fischer J, Nattermann J, D'Ambrosio R, McLeod D, Powell E, Latchoumanin O, Thabet K, Najim MAM, Douglas MW, Liddle C, Qiao L, George J, Eslam M; International Liver Disease Genetics Consortium (ILDGC).

Sci Rep. 2019 Feb 5;9(1):1439. doi: 10.1038/s41598-018-35736-2.

21.

Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study.

Brouwer WP, Chan HLY, Lampertico P, Hou J, Tangkijvanich P, Reesink HW, Zhang W, Mangia A, Tanwandee T, Montalto G, Simon K, Ormeci N, Chen L, Tabak F, Gunsar F, Flisiak R, Ferenci P, Akdogan M, Akyuz F, Hirankarn N, Jansen L, Wong VW, Soffredini R, Liang X, Chen S, Groothuismink ZMA, Santoro R, Jaroszewicz J, Ozaras R, Kozbial K, Brahmania M, Xie Q, Chotiyaputta W, Xun Q, Pazgan-Simon M, Oztas E, Verhey E, Montanari NR, Sun J, Hansen BE, Boonstra A, Janssen HLA; GIANT-B Global Consortium .

Clin Infect Dis. 2019 Nov 13;69(11):1969-1979. doi: 10.1093/cid/ciz084.

PMID:
30715261
22.

Hepatitis D - how is the fight against this foe going?

Loglio A, Segato S, Lampertico P.

Expert Rev Clin Pharmacol. 2019 Mar;12(3):169-171. doi: 10.1080/17512433.2019.1577135. Epub 2019 Feb 6. No abstract available.

PMID:
30698044
23.

JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1.

Zeuzem S, Bourgeois S, Greenbloom S, Buti M, Aghemo A, Lampertico P, Janczewska E, Lim SG, Moreno C, Buggisch P, Tam E, Corbett C, Willems W, Vijgen L, Fevery B, Ouwerkerk-Mahadevan S, Ackaert O, Beumont M, Kalmeijer R, Sinha R, Biermer M; OMEGA-1 study team.

Hepatology. 2019 Jun;69(6):2349-2363. doi: 10.1002/hep.30527. Epub 2019 Mar 14.

PMID:
30693573
24.

Evaluation of three "beyond Baveno VI" criteria to safely spare endoscopies in compensated advanced chronic liver disease.

Tosetti G, Primignani M, La Mura V, D'Ambrosio R, Degasperi E, Mezzina N, Viganò M, Rumi M, Fracanzani AL, Lombardi R, Fargion S, Fraquelli M, Aghemo A, Lampertico P.

Dig Liver Dis. 2019 Aug;51(8):1135-1140. doi: 10.1016/j.dld.2018.12.025. Epub 2019 Jan 11.

PMID:
30691777
25.

Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.

Degasperi E, D'Ambrosio R, Iavarone M, Sangiovanni A, Aghemo A, Soffredini R, Borghi M, Lunghi G, Colombo M, Lampertico P.

Clin Gastroenterol Hepatol. 2019 May;17(6):1183-1191.e7. doi: 10.1016/j.cgh.2018.10.038. Epub 2018 Oct 26.

PMID:
30613002
26.

Real life experiences in HCV management in 2018.

Viganò M, Andreoni M, Perno CF, Craxì A, Aghemo A, Alberti A, Andreone P, Babudieri S, Bonora S, Brunetto MR, Bruno R, Bruno S, Calvaruso V, Caporaso N, Cartabellotta F, Ceccherini-Silberstein F, Cento V, Ciancio A, Colombatto P, Coppola N, Di Marco V, Di Perri G, Fagiuoli S, Gaeta GB, Gasbarrini A, Lampertico P, Pellicelli A, Prestileo T, Puoti M, Raimondo G, Rizzardini G, Taliani G, Zignego AL.

Expert Rev Anti Infect Ther. 2019 Feb;17(2):117-128. doi: 10.1080/14787210.2019.1563755. Epub 2019 Jan 15. Review.

PMID:
30582384
27.

Impact of hepatitis C virus and direct acting antivirals on kidney recipients: a retrospective study.

Gendia M, Lampertico P, Alfieri CM, D'Ambrosio R, Gandolfo MT, Campise MR, Fabrizi F, Messa P.

Transpl Int. 2019 May;32(5):493-501. doi: 10.1111/tri.13393. Epub 2019 Jan 11.

PMID:
30580473
28.

Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir.

Viganò M, Loglio A, Labanca S, Zaltron S, Castelli F, Andreone P, Messina V, Ganga R, Coppola N, Marrone A, Russello M, Marzano A, Tucci A, Taliani G, Fasano M, Fagiuoli S, Villa E, Bronte F, Santantonio T, Brancaccio G, Occhipinti V, Facchetti F, Grossi G, Rumi M, Lampertico P.

Liver Int. 2019 Mar;39(3):484-493. doi: 10.1111/liv.14017. Epub 2019 Jan 7.

PMID:
30525275
29.

Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.

Testoni B, Lebossé F, Scholtes C, Berby F, Miaglia C, Subic M, Loglio A, Facchetti F, Lampertico P, Levrero M, Zoulim F.

J Hepatol. 2019 Apr;70(4):615-625. doi: 10.1016/j.jhep.2018.11.030. Epub 2018 Dec 7.

PMID:
30529504
30.

Endo-therapies for biliary duct-to-duct anastomotic stricture after liver transplantation: Outcomes of a nationwide survey.

Cantù P, Tarantino I, Baldan A, Mutignani M, Tringali A, Lombardi G, Cerofolini A, Di Sario A, Catalano G, Bertani H, Ghinolfi D, Boarino V, Masci E, Bulajic M, Pisani A, Fantin A, Ligresti D, Barresi L, Traina M, Ravelli P, Forti E, Barbaro F, Costamagna G, Rodella L, Maroni L, Salizzoni M, Conigliaro R, Filipponi F, Merighi A, Staiano T, Monteleone M, Mazzaferro V, Zucchi E, Zilli M, Nadal E, Rosa R, Santi G, Parzanese I, De Carlis L, Donato MF, Lampertico P, Maggi U, Caccamo L, Rossi G, Vecchi M, Penagini R.

Liver Int. 2019 Jul;39(7):1355-1362. doi: 10.1111/liv.14010. Epub 2019 May 22.

PMID:
30500104
31.

Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C.

D'Ambrosio R, Pasulo L, Puoti M, Vinci M, Schiavini M, Lazzaroni S, Soria A, Gatti F, Menzaghi B, Aghemo A, Capelli F, Rumi MG, Morini L, Giorgini A, Pigozzi MG, Rossini A, Maggiolo F, Pan A, Memoli M, Spinelli O, Del Poggio P, Saladino V, Spinetti A, De Bona A, Capretti A, Uberti-Foppa C, Bonfanti P, Terreni N, Menozzi F, Colombo AE, Giglio O, Centenaro R, Borghi M, Baiguera C, Picciotto V, Landonio S, Gori A, Magnani C, Noventa F, Paolucci S, Lampertico P, Fagiuoli S; NAVIGATORE-Lombardia Study Group.

J Hepatol. 2019 Mar;70(3):379-387. doi: 10.1016/j.jhep.2018.11.011. Epub 2018 Nov 23.

PMID:
30472321
32.

A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B.

Lampertico P, Messinger D, Cornberg M, Brunetto M, Petersen J, Kennedy P, Asselah T, Rothe V, Caputo A, Bakalos G, Pavlovic V, Papatheodoridis GV.

Ann Gastroenterol. 2018 Nov-Dec;31(6):712-721. doi: 10.20524/aog.2018.0300. Epub 2018 Jul 26.

33.

Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma.

Loglio A, Viganò M, Grossi G, Labanca S, Goldaniga M, Pompa A, Farina L, Rumi M, Corradini P, Facchetti F, Lunghi G, Baldini L, Lampertico P.

Dig Liver Dis. 2019 Mar;51(3):419-424. doi: 10.1016/j.dld.2018.08.024. Epub 2018 Sep 7.

PMID:
30316785
34.

[Direct-acting antiviral agents, hepatitis C and dialysis: an update].

Fabrizi F, Lampertico P, Messa P.

G Ital Nefrol. 2018 Sep;35(5). pii: 2018-vol5. Italian.

PMID:
30234230
35.

Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment.

Antonelli G, Gigante E, Iavarone M, Begini P, Sangiovanni A, Iannicelli E, Biondetti P, Pellicelli AM, Miglioresi L, Marchetti P, Lampertico P, Marignani M.

United European Gastroenterol J. 2018 Aug;6(7):1039-1048. doi: 10.1177/2050640618781188. Epub 2018 May 31.

36.

Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D.

Lampertico P, Brunetto MR, Craxì A, Gaeta GB, Rizzetto M, Rozzi A, Colombo M; HERMES Study Group.

J Viral Hepat. 2019 Jan;26(1):118-125. doi: 10.1111/jvh.12999. Epub 2018 Dec 11.

PMID:
30187599
37.

An easy-to-use baseline scoring system to predict response to peginterferon alfa-2a in patients with chronic hepatitis B in resource-limited settings.

Lampertico P, Messinger D, Oladipupo H, Bakalos G, Castillo M, Asselah T.

Antivir Ther. 2018;23(8):655-663. doi: 10.3851/IMP3251.

PMID:
29972138
38.

A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B.

El Sharkawy R, Thabet K, Lampertico P, Petta S, Mangia A, Berg T, Metwally M, Bayoumi A, Boonstra A, Brouwer WP, Smedile A, Abate ML, Loglio A, Douglas MW, Khan A, Santoro R, Fischer J, Leeming DJ, Liddle C, George J, Eslam M.

Aliment Pharmacol Ther. 2018 Sep;48(5):564-573. doi: 10.1111/apt.14866. Epub 2018 Jul 2.

PMID:
29963713
39.

A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B.

Chan HLY, Messinger D, Papatheodoridis GV, Cornberg M, Xie Q, Piratvisuth T, Ren H, Kennedy PT, Thompson A, Caputo A, Bakalos G, Pavlovic V, Lampertico P.

Aliment Pharmacol Ther. 2018 Sep;48(5):547-555. doi: 10.1111/apt.14862. Epub 2018 Jun 29.

PMID:
29956827
40.

Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B.

Loglio A, Iavarone M, Grossi G, Viganò M, Rumi MG, Facchetti F, Lunghi G, Sangiovanni A, Colombo M, Lampertico P.

Aliment Pharmacol Ther. 2018 Aug;48(4):431-439. doi: 10.1111/apt.14848. Epub 2018 Jun 19.

PMID:
29920698
41.

Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego AL, Brunetto MR, Raimondo G, Taliani G, Iannone A, Russo FP, Santantonio TA, Zuin M, Chessa L, Blanc P, Puoti M, Vinci M, Erne EM, Strazzabosco M, Massari M, Lampertico P, Rumi MG, Federico A, Orlandini A, Ciancio A, Borgia G, Andreone P, Caporaso N, Persico M, Ieluzzi D, Madonia S, Gori A, Gasbarrini A, Coppola C, Brancaccio G, Andriulli A, Quaranta MG, Montilla S, Razavi H, Melazzini M, Vella S, Craxì A; PITER Collaborating Group.

Liver Int. 2018 Dec;38(12):2190-2198. doi: 10.1111/liv.13901. Epub 2018 Aug 10.

42.

Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations.

Sangiovanni A, Triolo M, Iavarone M, Forzenigo LV, Nicolini A, Rossi G, La Mura V, Colombo M, Lampertico P.

Liver Int. 2018 Sep;38(9):1624-1634. doi: 10.1111/liv.13888. Epub 2018 Jul 15.

43.

Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal.

Manini MA, Whitehouse G, Bruce M, Passerini M, Lim TY, Carey I, Considine A, Lampertico P, Suddle A, Heaton N, Heneghan M, Agarwal K.

Dig Liver Dis. 2018 Sep;50(9):944-953. doi: 10.1016/j.dld.2018.03.032. Epub 2018 Apr 13.

PMID:
29735294
44.

High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma.

Persico M, Aglitti A, Aghemo A, Rendina M, Lleo A, Ciancio A, Di Marco V, Lampertico P, Brunetto MR, Zuin M, Andreone P, Villa E, Troshina G, Calvaruso V, Degasperi E, Coco B, Giorgini A, Conti F, Di Leo A, Marzi L, Boccaccio V, Bollani S, Maisonneuve P, Bruno S.

Aliment Pharmacol Ther. 2018 Jun;47(12):1705-1712. doi: 10.1111/apt.14685. Epub 2018 May 3.

PMID:
29722439
45.

High isavuconazole plasma levels in a patient with possible invasive pulmonary aspergillosis and cirrhosis.

Arsiè E, Piconi S, Iavarone M, Cozzi V, Lampertico P, Cattaneo D.

Eur J Clin Pharmacol. 2018 Aug;74(8):1089-1090. doi: 10.1007/s00228-018-2462-0. Epub 2018 Apr 18. No abstract available.

PMID:
29666903
46.

Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.

Fabrizi F, Aghemo A, Lampertico P, Fraquelli M, Cresseri D, Moroni G, Passerini P, Donato FM, Messa P.

Int J Artif Organs. 2018 Jun;41(6):306-318. doi: 10.1177/0391398818762358. Epub 2018 Mar 29.

PMID:
29595085
47.

12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis.

Degasperi E, Aghemo A, Paolucci S, D'Ambrosio R, Borghi M, Perbellini R, Novazzi F, De Nicola S, Lunghi G, Baldanti F, Lampertico P.

Dig Liver Dis. 2018 Jul;50(7):703-706. doi: 10.1016/j.dld.2018.02.003. Epub 2018 Feb 12.

PMID:
29499903
48.

Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.

Papatheodoridis GV, Sypsa V, Dalekos G, Yurdaydin C, van Boemmel F, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Loglio A, Siakavellas S, Gatselis N, Keskın O, Lehretz M, Savvidou S, de la Revilla J, Hansen BE, Kourikou A, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HLA, Berg T, Lampertico P.

J Hepatol. 2018 Jun;68(6):1129-1136. doi: 10.1016/j.jhep.2018.01.031. Epub 2018 Feb 8.

PMID:
29427727
49.

Treatment of hepatitis B: Is there still a role for interferon?

Viganò M, Grossi G, Loglio A, Lampertico P.

Liver Int. 2018 Feb;38 Suppl 1:79-83. doi: 10.1111/liv.13635. Review.

PMID:
29427498
50.

Less can be more: A finite treatment approach for HBeAg-negative chronic hepatitis B.

Lampertico P, Berg T.

Hepatology. 2018 Aug;68(2):397-400. doi: 10.1002/hep.29821. Epub 2018 May 14. No abstract available.

PMID:
29381811

Supplemental Content

Loading ...
Support Center